19:15 , Nov 9, 2018 |  BC Week In Review  |  Company News

NICE recommends Jazz's Vyxeos for AML

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Vyxeos daunorubicin/cytarabine to treat adults with newly diagnosed therapy-related acute myelogenous leukemia (AML) or AML with myelodysplasia-related changes. Vyxeos is a liposomal formulation of daunorubicin...
19:55 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

ViiV's two-drug HIV regimen meets again in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said a once-monthly two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III FLAIR trial as maintenance treatment in HIV-1-infected, antiretroviral therapy-naïve patients who are...
17:24 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

J&J, ViiV's two-drug regimen meets in Phase III for maintenance treatment of HIV-1 infection

ViiV Healthcare Ltd. (Brentford, U.K.) and Johnson & Johnson (NYSE:JNJ) said a two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III ATLAS trial as maintenance treatment in HIV-1-infected adults...
18:56 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
06:02 , Aug 10, 2018 |  BC Extra  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD); progressive supranuclear palsy (PSP) Patient sample and fly studies suggest PIWIL1 overexpression or inhibiting viral DNA polymerases could help treat AD, PSP and other tauopathies. In postmortem cortex and cerebellum samples...
21:09 , May 1, 2018 |  BC Innovations  |  Translation in Brief

Rewriting cancer’s origin story

A collection of 29 papers published across a suite of Cell journals in April by The Cancer Genome Atlas (TCGA) consortium completed the Pan-Cancer Atlas -- a comprehensive analysis of molecular signatures across cancer types....
00:00 , Apr 20, 2018 |  BC Innovations  |  Tools & Techniques

Structured outlook

A Cell study capturing hundreds of E. coli mRNA structures makes the case that complex, functionally relevant RNA structures are the rule, not the exception, and builds confidence that mRNAs -- once widely considered undruggable...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
01:13 , Feb 8, 2018 |  BC Extra  |  Company News

FDA approves Gilead's triple combo HIV therapy

Gilead Sciences Inc. (NASDAQ:GILD) said FDA approved Biktarvy bictegravir/emtricitabine/tenofovir alafenamide Wednesday to treat HIV-1 infection. Gilead told BioCentury it plans to launch the drug this week at a wholesale acquisition cost (WAC) of $2,945.65 for...